Are you ready to dive deep into the emerging field of #radiomics and #AI approaches in clinical-stage drug development and drug commercialization? Join us for an enlightening webinar hosted by Xtalks that will explore from high-level insights to real-world applications about the impact of AI and radiomics in #drugdevelopment. 🎙Save the date on your calendar and don't miss our panel of top-tier experts: Ronald Korn, Founder and Chief Medical Officer of Imaging Endpoints, Pamod Hemakumara, Director of Corporate Development at Quibim, and Fuensanta Bellvís Bataller, VP of Clinical Studies at Quibim. 💡 Learn about the potential impacts of radiomics and AI based technologies in modern drug development. 🗓️ Date: January 22, 2024 🕑 Time: 2pm EDT (11am PDT) Do not miss it! https://bit.ly/3vf9e3z
🌐 The J.P. Morgan Healthcare conference is just around the corner. We invite you to be part of the excitement in San Francisco from 8 to 11 of January. Immerse yourself in the future of healthcare as we showcase how we are transforming the industry through the power of #AI. 💡 Don't miss this opportunity to be at the forefront of healthcare innovation. Join us at the conference to learn and be part of the transformative journey that we are leading in the field of AI-based healthcare solutions. If you want to learn more, connect with us at https://lnkd.in/dU8z2qvb
The "ESR Statement on Validation of Imaging Biomarkers" delves into the unique challenges and methodologies in validating medical #imagingbiomarkers, and addresses issues related to sample acquisition and equipment variability, emphasizing the complexities arising from image quality differences. Key points: - #Radiologicimaging, unlike blood or urine acquisition, has inherent heterogeneity. - Validation of #analyticalmethods requires both technical and clinical evaluations. - #Metrology is crucial to validate imaging biomarkers, as are other measurement devices. Underscoring the need for a standardized methodology to reduce variability, ensure accuracy and improve patient care, this research advocates treating imaging biomarkers with the same rigor as traditional laboratory tests, recognizing the evolving nature of #medicalimaging. For a detailed understanding of imaging biomarkers, you can read the full article here: https://bit.ly/3TvrxvE
Excited to participate in the first consortium meeting of the FLUTE Project - AI & Prostate Cancer in Cesena, Italy. Quibim is leveraging the QP-Prostate tool to obtain accurate hashtag#prostate data, feeding Gradiant's hashtag#ProstateCancer model. Leading advanced hashtag#AI models with the Universitat Politècnica de Catalunya, we are improving data quality and driving project success. 🔒 This is another milestone in shaping the future of secure, collaborative healthcare hashtag#data analytics.
Acknowledging the pivotal role of #AI in advancing #PrecisionMedicine through multi-omics data integration, Quibim is at the forefront of transforming personalized #cancer treatments and addressing the complexities of tumor variability. These #DeepLearning models are essential in deciphering #cancer's molecular intricacies, laying the groundwork for tailored approaches in diagnosis, prognosis, and predicting treatment responses. Challenges like #data standardization, privacy concerns, and #AI interpretability remain. Still, advancements in these models are enhancing lesion detection and refining screening processes, leading to more precise evaluations of disease progression. 📖 Find out more in this complete article: https://bit.ly/3NMREe3 #AIInHealthcare #MedicalResearch #DigitalHealth
🌟 Quibim is a proud partner in European Federation for Cancer Images (EUCAIM), a project where we work together to establish a digital infrastructure for quantitative FAIR imaging biomarkers, while prioritizing hashtag#data sovereignty. Today we address a special message to the entire healthcare community: your views and opinions are more crucial than ever, as you play a pivotal role in creating a state-of-the-art medical imaging platform for hashtag#AI in healthcare. Fellow clinicians, innovators and researchers, we invite you to participate in this survey, which will only take about 10 minutes of your valuable time. By joining forces, we can drive scientific progress, foster innovation and raise healthcare standards across the continent! 💙 Link to the survey: https://lnkd.in/eGnTsswK
We are thrilled to announce our participation at the 65th American Society of Hematology (ASH) Annual Meeting, currently being held in San Diego. Today we are proud to present our poster "CART-AI-Radiomics: Survival and Neurotoxicity Prediction in B-Cell Lymphoma Patients Treated with CAR-T Cells through an Imaging Features-Based Model" in which we propose a model combining imaging features (MTVtotal, SUVmax and TLGtotal) with clinical variables measured before lymphodepletion (ICANS, C-reactive protein, LDH, lymphocytes count) that successfully predicts overall survival (p = 0.019) and progression-free survival (p = 0.007). A similar model also predicted the development of neurotoxicity with an AUC of 0.971, a sensitivity of 0.813, a specificity of 0.846 and an accuracy of 0.828. You can read the full article here: https://goo.su/qk1p #ASH2023 #DLBCL #PMBCL #CART #Radiomics #ImagingFeatures Gilead Sciences INCLIVA Instituto de Investigación Sanitaria La Fe Health Research Institute | IIS La Fe
🫱🏼🫲🏼 Founded on core principles such as accountability for owning one's actions, respect for colleagues, and transparency for open communication, every Quibim employee receives a badge of trust, symbolizing high standards, performance, and unwavering integrity. ➡️ Through our Whistleblower Channel, both Quibim employees and external parties can confidentially and anonymously report any suspected wrongdoing, unethical behavior, or illegal activities. This guarantees protection against any form of retaliation. 🔗 Access our Whistleblower Channel https://lnkd.in/dTyb95uS
🗣️ According to recent reports, 12,000 men die from #ProstateCancer each year, making it the most commonly diagnosed cancer without a national screening program in the UK. This situation could change with the TRANSFORM trial, now the largest prostate cancer screening trial in 20 years, backed by a £42 million budget. This trial, using advanced MRI technology, will screen hundreds of thousands of men across the country, potentially saving countless lives. 🤝 This initiative highlights the critical importance of early detection in the effective treatment of prostate cancer. By developing AI-based imaging solutions and collaborating with industry leaders, we are at the forefront of advancing prostate #cancer screening, detection, and personalized medical treatments. These organizations' collective efforts could save thousands of men's lives each year. For more information on this groundbreaking initiative, visit: https://bit.ly/41oxPPP #HealthInnovation #PrecisionMedicine
Our most recent study meticulously assesses the effectiveness of a nnU-Net deep learning tool in detecting and segmenting primary neuroblastoma tumors in #MRI scans. The study's objective is to externally validate a fully automated nnU-Net CNN algorithm for precise segmentation of neuroblastoma tumors. 🌐 Utilizing a diverse and multinational dataset of 300 children with neuroblastoma tumors and 535 T2-weighted MRI sequences, the results demonstrate a DSC of 0.997, indicating a 94% success rate in accurately locating and segmenting primary tumors. 🔎 Access the complete article here and discover the detailed findings: https://lnkd.in/e5RtyEDs #PediatricOncology #MedicalImaging #AIenHealth #ResearchHighlights
